10:29 AM EST - BriaCell Therapeutics Corp : Announces today that it has added Mayo Clinic, Jacksonville, Florida as a clinical site in the Phase I/II study of BriaCell’s lead candidate, Bria-IMT™, with Incyte’s PD-1 inhibitor, retifanlimab, in advanced breast cancer. BriaCell Therapeutics Corp
shares T.BCT are trading unchanged at $8.14.
